A five-phase model for clinical-outcome research
Department of Communication Disorders, University of Virginia, 2205 Fontaine Avenue, Suite 202, Charlottesville, VA 22908-0781, USA.Journal of Communication Disorders (Impact Factor: 1.45). 05/2004; 37(5):401-11. DOI: 10.1016/j.jcomdis.2004.04.003
Through a variety of approaches, speech-language pathologists and audiologists have produced strong evidence that treatments are generally potent. However, we have largely ignored the accepted standards for clinical-outcome testing used throughout the broader research community (e.g., by other clinical disciplines, federal regulators, and third-party payers). Several clinical professions recognize a comprehensive model for organizing and scaffolding the many forms of clinical-outcome research. An adaptation of this five-phase model of clinical-outcome research is examined as a means for structuring forms of clinical research throughout audiology and speech-language pathology. Within the organizing structure, relationships become apparent between types and grades of scientific evidence and the processes underpinning evidence-based practice which ultimately lead to decisions on the status of intervention protocols. LEARNING OUTCOMES: Readers will be able to distinguish the phases of clinical-outcome research in a comprehensive model. Readers will be able to identify relationships between the structure of the model and broadly recognized concepts associated with the terms 'efficacy' and 'effectiveness.' Readers will be able to identify indicators of quality for controlled clinical trials.
[Show abstract] [Hide abstract]
- "This implies that all costs and health benefits are included, regardless of to whom costs are related to or who receives the benefits (Drummond et al., 2005). In the field of speech and language pathology economic evaluations are scarce, but crucial to provide a basis for decisions on implementation and reimbursement of therapies (e.g., Robey, 2004). The aim of the present study was to determine the incremental cost– effectiveness and cost–utility of the LP compared to DCM based treatment. "
ABSTRACT: Purpose: The purpose of this study was to evaluate the incremental cost-effectiveness and cost-utility of the Lidcombe Program (LP) compared with treatment based on the Demands and Capacities Model (RESTART-DCM) for preschool children who stutter. Method: A cost-effectiveness and cost-utility analysis were carried out alongside a Randomized Clinical Trial (the RESTART-study). In total, 199 children in 20 speech clinics participated. Outcome measures included the number needed to treat, based on the percentage of children who did not stutter at 18 months, and Health-related Quality of Life (EQ-VAS and HUI3) at 3, 6, 12 and 18 months. Health-related Quality of Life scores were used to calculate quality adjusted life years (V-QALYs for the EQ-VAS and U-QALYs for the HUI3). Direct and indirect costs were measured by cost questionnaires. Missing data were multiply imputed. Percentages of children who did not stutter in both groups were compared by a chi-square test. Between-group differences in mean QALYs and costs, as well as cost effectiveness and cost-utility ratios, were evaluated by applying bootstrapping techniques. Results: After 18 months, health outcomes were slightly better in the LP group, although only the difference in V-QALYs was statistical significant (0.018; 95% CI: 0.008 to 0.027) with a small effect size (Cohen's d=0.17). Mean costs for the LP group were significantly higher compared to the RESTART-DCM group (€3199 versus €3032), again with a small effect size (Cohen's d=0.14). The incremental cost-effectiveness ratio was €3360 for one additional child who did not stutter with the LP, and the estimated cost-utility ratios were €10,413 (extra cost per extra V-QALY) and €18,617 (extra cost per extra U-QALY). The results indicated a high probability that the LP is cost-effective compared to RESTART-DCM treatment given a threshold for willingness-to-pay of €20,000 per QALY. Conclusions: Differences in effects and costs between the LP and RESTART-DCM treatment were small. Cost-effectiveness and cost-utility ratios were in favor of the LP. The LP is considered a good alternative to RESTART-DCM treatment in Dutch primary care.Journal of Communication Disorders 11/2015; 58:106-118. DOI:10.1016/j.jcomdis.2015.10.006
[Show abstract] [Hide abstract]
- "The present study is a Phase II study (Robey, 2004) in which the treatment was controlled in order to analyse the contribution of intensity to CILT for eight individuals with chronic aphasia. Several outcome measures were used to assess change including generalisation to discourse. "
ABSTRACT: Background: Studies of intensive aphasia treatments vary widely in terms of treatment focus, in patient population and, in particular, in definition of what is considered “intensive”. Variability makes it difficult to compare among studies and to definitively determine whether more treatment is actually better. Constraint-induced language therapy (CILT) is one treatment that has been successfully replicated at approximately the same dosage with generally positive results. Aims: The current study used a modified multiple baseline design across participants to investigate the administration of CILT at the standard intensive dosage of 30 hours over 2 weeks (CILT-I) compared to a more distributed dosage of 30 hours over 10 weeks (CILT-D). Methods & Procedures: Eight participants with chronic aphasia participated in either CILT-I or CILT-D. Standardised and discourse measures were taken pre- and posttreatment and also 4 weeks after the completion of treatment. Discourse probes were administered after every 6 hours of treatment to assess change in productivity and efficiency over time. Outcomes & Results: All of the participants who received CILT-I and CILT-D showed either an increased effect size on a discourse measure, a clinically significant change on a standardised battery or both. Gains were maintained in nearly all cases. Conclusions: CILT administered in both intensive and distributed dosages resulted in positive changes in aphasia severity and discourse. This study adds evidence to the still inconclusive role of intensity to CILT.Aphasiology 08/2015; DOI:10.1080/02687038.2015.1070949
[Show abstract] [Hide abstract]
- "often be limited by heterogeneous participants and insufficient experimental control measures (Byiers, Reichle, & Symons, 2012; Robey, 2004). No randomized control trials (RCTs) have been conducted to examine treatment efficacy for CAS (Morgan & Vogel, 2008, 2009; Watts, 2009). "
ABSTRACT: This randomized controlled trial compared the experimental Rapid Syllable Transition Treatment (ReST) to the Nuffield Dyspraxia Programme (3rd edition, NDP3), used widely in clinical practice in Australia and the United Kingdom. Both programs aim to improve speech motor planning/programming for children with apraxia of speech, but they differ in types of stimuli used, level of stimulus complexity at initiation of treatment, and the principles of motor learning that they apply. Treatment was delivered to 26 children with mild to severe CAS aged 4-12 years through trained and supervised speech-language pathology students in 1-hour sessions, 4 days a week for 3 weeks at a university clinic. Articulation and prosodic accuracy were assessed at pretreatment, 1 week, 1 month, and 4 months post-treatment using blinded independent assessors to compare treatment, maintenance and generalization effects. The ReST and NDP3 treatments demonstrated large treatment effects. ReST maintained treatment gains from 1 week to 4 months post-treatment more effectively than the NDP3. Significant generalization to untreated stimuli was observed for both ReST and NDP3. ReST and NDP3 have strong evidence of treatment and generalization gains in children with CAS when delivered intensively. Overall ReST has greater external evidence from multiple sources but both treatments have support for clinical use.Journal of Speech Language and Hearing Research 03/2015; 58(3). DOI:10.1044/2015_JSLHR-S-13-0179
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.